AI and mRNA Cancer Vaccine Shows 49% Reduction in Melanoma Relapse at ASCO 2026
Long-term data from ASCO 2026 shows the personalized cancer vaccine Intismeran Autogene, combined with Keytruda, reduces recurrence or death risk by 49% in high-risk melanoma patients. Developed by MSD and Moderna, the vaccine uses AI to select neoantigens from a patient's tumor and mRNA technology to create a personalized treatment. The results signal a major advance for a field that had struggled for decades, spurring similar development efforts by other companies.
Personalized cancer vaccines are showing significant promise, with new long-term data demonstrating a 49% reduction in recurrence or death for high-risk melanoma patients. The breakthrough results, presented at the American Society of Clinical Oncology (ASCO 2026) meeting in Chicago from May 29 to June 2, highlight the combined impact of artificial intelligence (AI) and messenger RNA (mRNA) technology in the fight against cancer recurrence.
The five-year follow-up data from drugmakers MSD and Moderna focused on their jointly developed personalized cancer vaccine, Intismeran Autogene (mRNA-4157/V940). In the study, when Intismeran Autogene was administered in combination with the immunotherapy Keytruda (pembrolizumab) to high-risk melanoma patients, it reduced the risk of recurrence or death by 49% and the risk of distant metastasis or death by 59%. Cancer vaccines are designed as therapies for patients who already have cancer, helping their immune cells attack cancer cells more effectively to prevent the disease from returning.
Intismeran Autogene is considered the personalized cancer vaccine candidate closest to commercialization. The process involves analyzing the genetic information of a patient's tumor. AI then selects up to 34 mutation antigens (neoantigens) that exist only on the cancer cells, which are packaged into an individualized vaccine. The treatment is co-developed with Keytruda to guide immune cells to recognize the cancer cells precisely.
For more than two decades, attempts to develop effective cancer vaccines largely failed due to the difficulty of identifying precise targets on cancer cells, as their genetic characteristics vary by patient. The convergence of advanced AI, next-generation genome analysis, and mRNA technology is seen as the turning point. AI helps identify mutation candidates and select targets with the highest likelihood of inducing an immune response. mRNA technology, which was commercialized during the COVID-19 pandemic, can translate this mutation antigen information into a vaccine relatively quickly, enabling truly personalized treatment.
The success of this approach is spurring development across the pharmaceutical industry. Germany's BioNTech and Switzerland's Roche are developing the personalized cancer vaccine candidate BNT122 targeting pancreatic and colorectal cancers. In early research, the patient cohort that responded to the vaccine showed longer recurrence-free survival, and follow-up clinical trials are underway. Swiss biotech Nouscom is developing a preventive cancer vaccine for patients with Lynch syndrome, who have a high genetic risk of cancer.
Despite the promising results, significant hurdles remain for commercializing cancer vaccines. Because each vaccine must be manufactured individually for every patient, there are substantial manufacturing expenses and production time issues to overcome. Additional validation is also required to determine in which cancer types the vaccine will be most effective.
Research and development is also advancing in other regions. In Korea, the NeoVax-K Consortium has embarked on developing personalized mRNA cancer vaccines through a national project. The consortium, led by Aston Science and including partners Theragen Bio, IMBdx, Genedit, and Korea University Anam Hospital, is working to build a platform targeting pancreatic and colorectal cancers, as well as pediatric and adolescent cancers.
The broader application of AI to improve cancer care is also expanding. The Mount Sinai Tisch Cancer Center has launched a new AI platform called PRISM, created by the AI company Triomics. The platform, powered by Triomics’ OncoLLM large language model, is designed to connect cancer patients across the Mount Sinai Health System to clinical trials, aiming to expand access to innovative research and accelerate enrollment.